I didn't find the 10Q any reason for positive move
Post# of 72440
(Total Views: 373)
Posted On: 11/09/2017 9:44:10 AM
I didn't find the 10Q any reason for positive movement of stock but for some reason SP is rising.
A good poster on another board found this in the 10Q and it is quite positive IMO.
This is interesting! IMO. Under note 2 going concern and liquidity. I think it was around page 7 or 8. This is much much different than previous Qs. Each Q seems to be different. One Q back Leo was taking about possibly having to take an upfront license fee for possibly much less than wanted because of current stage of dev. Now this one:
Accordingly, the Company’s planned operations, including total budgeted expenditures of approximately $15 million for the next twelve months, raise doubt about its ability to continue as a going concern. The Company’s plans to alleviate the doubt of its ability to continue as a going concern primarily include controlling the timing and spending on its research and development programs and raising additional funds through equity financings from its common stock purchase agreement with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”). The Company may consider other plans to fund operations including: (1) raising additional capital through debt financings or from other sources; (2) additional funding through new relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. The Company may issue securities, including shares of common stock, shares of preferred stock and stock purchase contracts through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-3 filed with the SEC on September 11, 2017. The Company’s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.
The Company believes that the actions discussed above are probable of occurring and alleviating the substantial doubt raised by our historical operating results and satisfying our estimated liquidity needs twelve months from the issuance of the accompanying financial statements.
This last paragraph has a much better tone IMO. Obviously I'm a bull here....but if you go back and read the same section on the previous Q's I think you will agree.
A good poster on another board found this in the 10Q and it is quite positive IMO.
This is interesting! IMO. Under note 2 going concern and liquidity. I think it was around page 7 or 8. This is much much different than previous Qs. Each Q seems to be different. One Q back Leo was taking about possibly having to take an upfront license fee for possibly much less than wanted because of current stage of dev. Now this one:
Accordingly, the Company’s planned operations, including total budgeted expenditures of approximately $15 million for the next twelve months, raise doubt about its ability to continue as a going concern. The Company’s plans to alleviate the doubt of its ability to continue as a going concern primarily include controlling the timing and spending on its research and development programs and raising additional funds through equity financings from its common stock purchase agreement with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”). The Company may consider other plans to fund operations including: (1) raising additional capital through debt financings or from other sources; (2) additional funding through new relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. The Company may issue securities, including shares of common stock, shares of preferred stock and stock purchase contracts through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-3 filed with the SEC on September 11, 2017. The Company’s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.
The Company believes that the actions discussed above are probable of occurring and alleviating the substantial doubt raised by our historical operating results and satisfying our estimated liquidity needs twelve months from the issuance of the accompanying financial statements.
This last paragraph has a much better tone IMO. Obviously I'm a bull here....but if you go back and read the same section on the previous Q's I think you will agree.
(3)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼